Mayo Clinic | Strategic Alliance Partners

December 06, 2023

Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.

December 06, 2023

The impact of and strategies for addressing less frequent mutations in NSCLC treatment decisions, emphasizing actionable alterations and timely interventions in challenging scenarios.

November 29, 2023

Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.

November 29, 2023

Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.

November 21, 2023

Closing out their panel, experts discuss the potential of blood-based tests to democratize access to cancer screening, complement existing protocols, and achieve early detection goals in the fight against cancer.

November 21, 2023

Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection.

November 17, 2023

Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.

November 17, 2023

Explore the latest breakthroughs in precision medicine with a focus on biomarker testing and emerging targets in patients with non–small cell lung cancer.

November 14, 2023

Explore the pivotal role of the Moonshot Cancer Initiative and MCED Consortium in shaping the landscape of early cancer detection and screening, with a focus on innovative screening tools and legislative support.

November 14, 2023

Implementation challenges and the importance of equitable access in the future of multi-cancer early detection tests.

November 07, 2023

Shared insight into the efficiency of diagnostic resolution approaches, comparing imaging-based and molecular tissue of origin strategies in multi-cancer early detection testing.

November 07, 2023

Expert perspectives about the ASCEND trial, its study design, and the critical role it plays in developing advanced cancer detection methods.

October 31, 2023

Discover the potential clinical implications of groundbreaking cancer screening studies, DETECT-A and PATHFINDER, and the evolving landscape of multi-cancer early detection.

October 26, 2023

Ricardo D. Parrondo, MD, highlights the current use of covalent BTK inhibitors in chronic lymphocytic leukemia, potential roles for the non-covalent BTK inhibitor pirtobrutinib, and the importance of future research on time-limited treatment options for patients with newly diagnosed chronic lymphocytic leukemia.

October 26, 2023

While progress in outcomes has been greater in non–small cell lung cancer, recent advances, including molecularly targeted therapies against EGFR and ALK, checkpoint inhibitors that boost immune response, improved staging, and video-assisted surgery have all contributed to progress in treatment of all types of lung cancer, including in SCLC.

October 24, 2023

Panelists explore recent findings of the PATHFINDER study, focusing on the objectives, study design, key results, and differences from previous studies, shedding light on the potential of early cancer detection tests.

October 24, 2023

Shared insight into findings of the DETECT-A study, a prospective interventional trial, covering feasibility, safety, and performance of multicancer early detection tests in a healthcare system setting.

October 23, 2023

Ricardo D. Parrondo, MD, discusses the current treatment landscape of mantle cell lymphoma and highlights ongoing areas of investigation in other hematologic malignancies.

October 20, 2023

Lance C. Pagliaro, MD, discusses the efficacy of first-line avelumab maintenance therapy, as seen in the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

October 20, 2023

Muhamad Alhaj Moustafa, MD, MS, discusses the evolution of treatment options for patients with mantle cell lymphoma.